76 results about "Favipiravir" patented technology

The invention relates to a favipiravir intermediate and a synthetic method for favipiravir, and specifically discloses a method for synthesizing 3,6-difluoro-2-cyanopyrazine with a formula 4 as shownin the specification. The method comprises the following steps: a) allowing a compound with a formula 1 as shown in the specification to react with a chlorinated reagent or a brominated reagent so asto obtain a compound with a formula 2 as shown in the specification; b) allowing the compound with the formula 2 as shown in the specification to react with phosphorus oxychloride in the presence of organic base so as to obtain a compound with a formula 3 as shown in the specification; and c) allowing the compound with the formula 3 as shown in the specification to react with a fluorinated reagentso as to obtain the compound with the formula 4 as shown in the specification. The invention also relates to a method for synthesizing the favipiravir by using the above-mentioned method.

The invention discloses an HPLC method for measuring related substances in Favipiravir. According to the HPLC method for measuring related substances in Favipiravir, disclosed by the invention, specifically, a diode array detector is adopted, and acetonitrile (mobile phase A)-phosphate solution (mobile phase B) serves as a mobile phase. The method comprises the following steps: taking a proper amount of Favipiravir and related preparations containing Favipiravir, adding the substances into the mobile phase for preparing a solution of which every 1ml contains 0.2mg of Favipiravir, and taking the solution as a test solution; diluting into a solution of which every 1ml contains about 0.2mu g of Favipiravir by using the mobile phase, and taking the solution as a contrast solution; respectively performing sample introduction, wherein the sum of each impurity peak area in the chromatogram of the test solution is not more than the main peak area of the contrast solution. According to the method for detecting the related substances in Favipiravir and related preparations containing Favipiravir, disclosed by the invention, the conditions of the impurities and degradation products of Favipiravir can be rapidly and accurately detected. The operation is simple and convenient, the sensitivity is high, and the product quality can be well controlled.

The invention relates to a favipiravir tablet composition, which belongs to the technical field of pharmaceutical preparations. The technical scheme of the present invention is: a kind of favipiravir tablet composition, in the composition of unit dose, containing D90 is less than 40 microns, and D50 is 200mg of favipiravir at 26-33 microns, microcrystalline cellulose 24‑45mg, lactose 10‑18mg, macrogol 6000 8‑16mg, sodium lauryl sulfate 0.8‑1.3mg, meteorological silica 2‑5mg, magnesium stearate 1‑2.5mg. The invention provides a qualified favipiravir tablet, which solves the defects that the tablet has pits and the dissolution rate decreases as the storage time prolongs.

The invention discloses a favipiravir synthesis method, which comprises the following steps that (1) a pyrazine compound is dissolved in an organic reagent I; nitrogen oxidation reaction is performed to obtain white solid matters; (2) the white solid matters of pyrazine dinitrogen oxides are added into an organic reagent II to perform chlorination reaction; light yellow solids are obtained; (3) the obtained light yellow solids, a dry aprotic polar solvent, a dry fluorion donor reagent and tetrabutylammonium bromide are uniformly mixed; stirring reaction is performed to obtain light yellow solids; (4) the prepared 3,6-dichloropyrazine-2-formonitrile and a fluorizating agent perform aromatic ring fluoronation; (5) hexafluoro reaction products are directly catalyzed through hydrogen peroxide; cyan-hydrolysis reaction is performed; (6) cyan-hydrolysis reaction products are directly catalyzed through an aqueous alkaline solution; aromatic ring hydroxyl substitution reaction is performed; then, through purification treatment, favipiravir is prepared. The method disclosed by the invention has the advantages that the raw materials are simple and are easily to obtain; the synthesis process is simple; good industrial value is realized; green and environment-friendly effects are achieved.

The invention relates to a fapiravir and a preparation method of an intermediate thereof, and belongs to the field of pharmaceutical chemicals. The invention provides a preparation method of a fapiravir intermediate 3-hydroxy sodium pyrazine-2-formamide, wherein the fapiravir intermediate 3-hydroxy sodium pyrazine-2-formamide is prepared by reacting aminopropanedioide with lithium chloride in thepresence of a NaOH solution and glyoxal. The invention also provides a preparation method of 6-bromo-3-hydroxy pyrazine-2-formamide, wherein the 6-bromo-3-hydroxy pyrazine-2-formamide is prepared froman acetonitrile solution of 3-hydroxy sodium pyrazine-2-formamide and an acetonitrile solution of liquid bromine in a microchannel reactor. The invention also provides a preparation method of 3, 6-difluoropyrazine-2-formamide, wherein the 3, 6-difluoropyrazine-2-formamide is prepared by reacting 6-bromo-3-hydroxy pyrazine-2-formamide with potassium bifluoride in the presence of PEG-400 and DMF. Finally, the invention also provides a total synthesis method for preparing fapiravir from the intermediate. The reactions avoid the use of highly dangerous diazotization reactions, and the methods have the advantages of high safety, low raw material price, short steps, low cost and simple post-treatment, and are suitable for industrial enlarged production.

The invention relates to a new crystal form of favipiravir, which belongs to the technical field of preparation of raw materials. The technical solution of the present invention is: a new crystal form of favipiravir. In the powder X-ray diffraction of the crystal form, the 2θ° is 7.4, 8.5, 11.1, 15.4, 17.8, 18.5, 19.2, 21.0, 21.8, 22.6, There are strong absorption peaks near 23.5 and 26.4. The technical solution of the present invention provides a favipiravir crystal form with good solubility, which plays a positive role in the improvement of the favipiravir preparation.

The invention relates to a stable favipiravir injection and a preparation method thereof. The stable favipiravir injection comprises favipiravir, a solubilizer sulfobutyl ether-beta-cyclodextrin sodium and an acid-base regulator. The stable favipiravir injection can endure terminal sterilization and has good safety and stability.

The invention discloses a compound crystal, and a preparation method and application thereof, belonging to the technical field of chemical medicines. The compound crystal is a eutectic crystal of favipiravir and p-aminobenzoic acid, the unit cell of the eutectic crystal belongs to a monoclinic system and a P21/c space group, and the unit cell parameters are as follows: alpha = gamma = 90 degrees and beta = 92.578 (3) degrees. The equivalent solubility of the favipiravir in the compound crystal provided by the invention is reduced by about 50%, so that the dissolution rate of the favipiravir is favorably reduced, the onset time of the favipiravir is prolonged, and the toxic and side effects of the favipiravir are reduced.

The invention relates to the technical field of medicine synthesis, and in particular, relates to a synthesis process of favipiravir and an intermediate thereof. The synthesis method of favipiravir comprises the following steps: 1) 2-aminopropanediamide and glyoxal serve as raw materials, and generating a compound III through a cyclization reaction; 2) performing benzyl protection on the compoundIII under the catalysis of potassium carbonate to generate a compound IV; 3) performing fluorine substitution on the compound IV under the action of fluorine gas, a solvent and a catalyst to generatea compound V; and 4) performing debenzylation protection on the compound V to generate favipiravir. Compared with other synthetic routes of favipiravir, the synthetic route provided by the invention has the advantages that the whole process route is shortened by virtue of high-selectivity fluorination reaction, the production cost is greatly reduced, and the synthesis process is suitable for industrial production.

The invention relates to the field of analytical chemistry, and discloses a method for detecting related substances of favipiravir, which takes a phosphate solution (mobile phase A)-acetonitrile (mobile phase B) as a mobile phase and a sodium carbonate solution as a diluent. taking a proper amount of favipiravir and a proper amount of a tablet containing the favipiravir, adding a diluent to prepare a sample solution containing 0.5 mg/mL of the favipiravir, and adding the diluent to dilute the favipiravir into a reference substance solution of 2.5 [mu] g/mL; quantitatively determining the contents of related substances in the favipiravir and the preparation by adopting a main component and correction factor method. According to the method for detecting the related substances of the favipiravir , the conditions of impurities and degradation products of the favipiravir can be rapidly and accurately detected. Operation is easy and convenient, accuracy is good, sensitivity is high, and product quality can be well controlled.

The invention provides a novel preparation method of a favipiravir derivative. Specifically, a fluorinating reagent is directly used for an electrophilic fluorination reaction, fluorine atoms are selectively introduced to the 6-position, and favipiravir or the derivatives thereof are efficiently synthesized through one-step reaction. Compared with the existing synthesis method, the synthesis method adopting one-step reaction has the advantages of strong creativity, novelty, simplicity in operation, safety, low cost, less three wastes, environmental friendliness and high total yield, so that the synthesis method has extremely strong industrial advantages and significance.

The invention relates to a preparation method of a favipiravir impurity 6-chloro-3-hydroxy-2-pyrazinecarboxamide shown as formula (1). By preparing the favipiravir impurity, and providing a referencesubstance for qualitative and quantitative analysis of favipiravir impurity, the invention improves the quality standard of favipiravir, and provides important guidance for safe medication of favipiravir.

A composition and method for treating a mammal infected with a virus therein, and an inhalation delivery system for prevention and treatment of upper respiratory tract viruses, by administering a therapeutic dose of the composition to the mammal. The composition includes:

• • microparticles and/or nanoparticles, wherein a pharmaceutically active agent, corticosteroid and/or hydroxychloroquine, niclosamide, and/or favipiravir, and a zinc salt are incorporated in the microparticles and/or nanoparticles. The pharmaceutically active agent is unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH), other glycosaminoglycans (GAGs), or combinations thereof.

The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.

The invention particularly relates to a favipiravir medicinal conjugate and an application thereof to preparation of an antiviral medicinal preparation. Favipiravir is a broad-spectrum antiviral drugwith a good prospect, but the favipiravir is poor in water solubility and low in bioavailability. The invention provides a medicinal conjugate form of the favipiravir, and theophylline and piperazineare adopted as forming substances of eutectic crystals and salt, so that the solubility of the favipiravir in water is remarkably improved, and a new research thought is provided for development of afavipiravir drug combined application mode and dosage forms.

The invention relates to an anti-influenza virus compound as well as a preparation method and an application thereof, and belongs to the technical field of pharmaceutical synthesis. The compound contains oseltamivir and favipiravir structures and has the structure shown in the formula II in the description. The method comprises the following steps: oseltamivir and methyl chloroformate are subjected to condensation reaction, a compound (I) (3R,4R,5S)-4-acetamido-5-[chloromethoxycarbonyl]amino-3-(1-propoxyethyl)- -1-cyclohexane-1-carboxylic ethyl ester is obtained; the compound (I) and favipiravir are linked by nucleophilic substitution reaction, and a target compound (II) is obtained. The compound (II) has different degrees of inhibiting effects on H5N2, H5N6 and H5N8, and has better antiviral activity on H5N2 in vitro. Therefore, the invention also provides the application of the compound shown in the formula II in preparation of anti-influenza virus medicines.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of a favipiravir intermediate 2-aminomalonamide. According to the method, diethyl 2-nitrosomalonate is used as a starting raw material, Raney nickel is used as a catalyst for hydrogenation reduction to obtain dimethyl 2-aminomalonate, and then aminolysis is performed to obtain 2-aminomalonamide. Raney nickel is used as a catalyst, so that the problem that palladium carbon is easy to inactivate can be effectively avoided. Raney nickel has good tolerance to the raw materials, the inactivation phenomenon is not prone to occurring, and the defect that organic impurities such as phosphorus and sulfur exist in the raw materials can be well overcome. Compared with palladium carbon, Raney nickel is cheaper, and the production cost is reduced to a certain extent through the preparation method.

The invention relates to a preparation method of favipiravir. The preparation method comprises the following steps: dissolving 6-bromine-3-hydroxypyrazine-2-formamide in a first solvent, adding a first fluorinating agent, and carrying out a stirring reaction so as to prepare 6-bromine-3-fluoropyrazine-2-formamide; dissolving the 6-bromo-3-fluoropyrazine-2-formamide, a second fluorinating agent anda catalyst in a second solvent, and carrying out a heating reaction to prepare 6-fluoro-3-fluoropyrazine-2-formamide; and carrying out hydroxyl substitution on the 6-fluoro-3-fluoropyrazine-2-formamide to prepare the favipiravir. The invention further discloses a preparation method of the favipiravir. The preparation method of favipiravir has the advantages of simple and safe reaction operation,less three wastes, green and environment-friendly synthetic route and environmental friendliness; the favipiravir has the advantages of higher yield, stability and low production cost, and is suitablefor industrial production.

The invention relates to a method for refining favipiravir and/or derivatives thereof, which comprises the following steps of dissolving favipiravir and/or derivatives thereof to be refined in an organic solvent A, filtering with silica gel, drying and purifying to obtain the favipiravir. The purification is selected from any one or a combination of recrystallization and pulping. According to the refining method, the problem that favipiravir is difficult to decolor is solved, and the obtained product is a white or off-white powdery product and meets related requirements of drug quality standards. In addition, the method is suitable for purification and decoloration of other products and intermediates, and is high in decoloration degree, good in purification effect, simple and convenient to operate, low in cost and suitable for industrial production.